New CAR T-Cell attack on tough blood cancers shows early promise
NCT ID NCT06191887
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 30 times
Summary
This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to 27 adults with relapsed or refractory B-cell blood cancers like lymphoma or leukemia. The main goals are to find the safest dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.